Aclaris Therapeutics (ACRS) Income from Continuing Operations: 2017-2025
Historic Income from Continuing Operations for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$15.3 million.
- Aclaris Therapeutics' Income from Continuing Operations fell 80.78% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 279.49%. This contributed to the annual value of -$132.1 million for FY2024, which is 49.26% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Income from Continuing Operations is -$15.3 million, which was up 6.47% from -$16.4 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Income from Continuing Operations peaked at -$1.9 million during Q4 2023, and registered a low of -$97.6 million during Q4 2024.
- In the last 3 years, Aclaris Therapeutics' Income from Continuing Operations had a median value of -$16.4 million in 2025 and averaged -$25.0 million.
- In the last 5 years, Aclaris Therapeutics' Income from Continuing Operations spiked by 93.61% in 2023 and then slumped by 5,151.45% in 2024.
- Over the past 5 years, Aclaris Therapeutics' Income from Continuing Operations (Quarterly) stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then soared by 93.61% to -$1.9 million in 2023, then slumped by 5,151.45% to -$97.6 million in 2024, then crashed by 80.78% to -$15.3 million in 2025.
- Its last three reported values are -$15.3 million in Q3 2025, -$16.4 million for Q2 2025, and -$15.9 million during Q1 2025.